Company OverviewAlpha Cognition Inc.
Alpha Cognition (CVE: ACOG) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).
Two programs are in development; ALPHA-1062, a prodrug of galantamine is entering its pivotal study for the treatment of mild to moderate dementia of the Alzheimer’s type and ALPHA-0602, is in preclinical development for ALS.
Our company is head-quartered in Vancouver, British Columbia (Canada) with laboratory facilities in Charlottetown, Prince Edward Island (Canada) and the US subsidiary is located in West Palm Beach, Florida (USA).
Speaker BioPresident
Alpha Cognition, Inc.
Dr. Sancilio has over 35 years of experience in pharmaceutical development and research. He has founded several biopharmaceutical companies including aaiPharma (CDMO renamed Alcami), Endeavor Pharmaceuticals (acquired by Barr Laboratories now Teva) and Aesgen Inc. (now owned by Pfizer). Dr. Sancilio has been a board member of both public and private pharmaceutical companies. More recently, he served as Research Professor at Florida Atlantic University. He was elected as a member of Sigma Xi, the Scientific Research Society of North America and holds both a Master’s and Doctorate degree from Rutgers, the State University of New Jersey.
